Hi Reg,
"...Also in that article is price per vial - with Si indicating pricing over 500k in pediatric SR aGvHD...."
IMO that''s conservative.
Not sure if I've mentioned this previously, but I understand from recent Mesoblast' shareholder briefings, including the AGM and Feb 29 2024 Earnings call:
1. the reason that we are in the USA (and not in EU) with Remestemcel-l seeking initial marketing approval is principally the compelling economics of USA reference pricing; and
2. the pricing for Remestemcel-l for paediatric SR-aGVHD would be:
- only comparable to that of a curative paediatric drug (rated in terms of assessed Qualty-Adjusted-Life-Year benefit). Note that Amtagvi (Iovance), approved in Feb 2024 uses TIL cell therapy, is presently priced at USD515,000 (not including hospital fees and side-effect addressing drugs), has very significant side effects and is not considered generally curative,
- priced in a range having, as a lower limit i.e. a minimum under any circumstances, the current CAR T-cell therapies pricing i.e. USD375,000 to USD500,000
- in MSB execs estimation, significantly in excess of USD500k per treatment. CEO Itescu's exact words at the February 29 shareholder call were, in part:
" ...And I think when you -- some of the gene therapies that are providing that kind of curative outcome charge some pretty remarkable prices.
I would say that we would see that pricing for this product is somewhere between the CAR-T products and the curative gene therapy products... "
What are those curative gene therapy prices? Here's a list as at 25 March 2024 of the most prominent of the approved cell and gene therapy products available in the US atm. I think everyone will be able to tell which ones are considered the curative gene therapy products:
Link HERE. The article had this example to give of ICER's cost-effective pricing calculation in the US at the moment:
" Assuming a five-year event-free survival rate of 35% with second-line Yescarta and 10% with standard of care, Yescarta was cost effective at a willingness to pay ratio of $150,000 per QALY, as DrugTopics summarized. Yet Yescarta was no longer cost-effective if its 5-year event-free survival was less than or equal to 26.4% or if it cost more than $972, 061 at a willingness-to-pay threshold of $150,000."
The article goes on to point out that cost-effectiveness assumptions are still being made about the long-term benefits associated with Zolgensma, for example. The authors comments seeméd to me to highlight Mesoblast' products relative cost-effectiveness advantages, viz:
" Ultimately, whether cell and gene therapies can deliver on their clinical promise while justifying their frequently high costs will become clearer in the coming years as more long-term data become available.
The durability of treatment benefits remains a critical consideration; a frequent argument for the therapy class is that one-time therapies with lifelong effects are far more cost-effective than those requiring repeat administration.
The size of the treatable patient population is another important dimension, with ultra-rare disease therapies facing a steeper challenge in recouping development costs than treatments for more prevalent conditions.
Finally, the availability of alternative treatments, even if less effective, can raise the cost-effectiveness bar for new gene therapies.": (emphasis added)
I think Mesoblast' management are very focussed, and I expect that MSB's products will be viewed as realtively curative compared with these therapies. Those 4yr-plus long-term survival statistics for Remestemcel-l will be critical IMO.
Cheers & have a good one.
GLTA(LT)H
- Forums
- ASX - By Stock
- MSB
- Ann: FDA Grants Orphan Drug Designation for Revascor
Ann: FDA Grants Orphan Drug Designation for Revascor, page-236
-
- There are more pages in this discussion • 37 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.13 |
Change
0.035(3.21%) |
Mkt cap ! $1.284B |
Open | High | Low | Value | Volume |
$1.09 | $1.13 | $1.07 | $3.910M | 3.535M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 27197 | $1.11 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.13 | 43578 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 31763 | 1.100 |
2 | 33264 | 1.090 |
2 | 18897 | 1.085 |
2 | 18926 | 1.080 |
1 | 18000 | 1.075 |
Price($) | Vol. | No. |
---|---|---|
1.130 | 23400 | 3 |
1.135 | 1090 | 1 |
1.140 | 65000 | 4 |
1.145 | 64500 | 3 |
1.150 | 92314 | 9 |
Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |